Johnson & Johnson Highlights Promising First-In-Human Erda-iDRS Results in Intermediate risk Non-Muscle-Invasive Bladder Cancer
March 14, 2026
March 14, 2026
RARITAN, New Jersey, March 14 -- Johnson and Johnson Innovative Medicine issued the following news release on March 13, 2026:
* * *
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate risk non-muscle-invasive bladder cancer
- Data presented at EAU 2026 show an 89 percent complete response rate in intermediate risk disease with durable responses observed over 18 months and tolerable safety profile
* * *
Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate risk non-muscle-invasive bladder cancer
- Data presented at EAU 2026 show an 89 percent complete response rate in intermediate risk disease with durable responses observed over 18 months and tolerable safety profile